TICKERNOMICS Sign up
Last Update: 2023-12-23 06:05:01
Tharimmune Inc. ( HILS ) https://www.hillstreambio.com
2.88USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-68.06%
HILS
SPY
30.72%
HILS
0.00%
SPY
112.82%
HILS
0.00%
SPY
201.04%
HILS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
49.72
47.03
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.03
0.00
28.30
0.00
0.00
-4.63
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-393.46
-1074.88
0.00
Other Earnings and Cash Flow Stats:
Tharimmune Inc. ( HILS ) Net Income TTM ($MM) is -1602.79
Tharimmune Inc. ( HILS ) Operating Income TTM ($MM) is -8.45
Tharimmune Inc. ( HILS ) Owners' Earnings Annual ($MM) is 0.00
Tharimmune Inc. ( HILS ) Current Price to Owners' Earnings ratio is 0.00
Tharimmune Inc. ( HILS ) EBITDA TTM ($MM) is -9.96
Tharimmune Inc. ( HILS ) EBITDA Margin is 0.00%
Capital Allocation:
Tharimmune Inc. ( HILS ) has paid 0.00 dividends per share and bought back -5.762214 million shares in the past 12 months
Tharimmune Inc. ( HILS ) has reduced its debt by 3.557987 million USD in the last 12 months
Capital Structure:
Tharimmune Inc. ( HILS ) Interest-bearing Debt ($MM) as of last quarter is 0
Tharimmune Inc. ( HILS ) Annual Working Capital Investments ($MM) are -1
Tharimmune Inc. ( HILS ) Book Value ($MM) as of last quarter is 1
Tharimmune Inc. ( HILS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Tharimmune Inc. ( HILS ) has 2 million in cash on hand as of last quarter
Tharimmune Inc. ( HILS ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Tharimmune Inc. ( HILS ) has 17 common shares outstanding as of last quarter
Tharimmune Inc. ( HILS ) has 0 million USD of preferred stock value
Academic Scores:
Tharimmune Inc. ( HILS ) Altman Z-Score is 2.94 as of last quarter
Tharimmune Inc. ( HILS ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Tharimmune Inc. ( HILS ) largest shareholder is owning shares at 0.00 ($MM) value
Randy Milby(an insider) Bought 500 shares of Tharimmune Inc. ( HILS ) for the amount of $390.00 on 2022-06-17
38.91% of Tharimmune Inc. ( HILS ) is held by insiders, and 0.89% is held by institutions
Tharimmune Inc. ( HILS ) went public on 2022-01-12
Other Tharimmune Inc. ( HILS ) financial metrics:
FCF:-7.26
Unlevered Free Cash Flow:0.00
EPS:-0.42
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-414.39
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Tharimmune Inc. ( HILS ) :
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.